πŸ‡ΊπŸ‡Έ FDA

Intelligence Β· Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors β€” phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text β€” searchable for business development and competitive intelligence.

7,888 results for β€œ1” Clear

  1. An Adaptive Dose Escalation and Expansion BasketΒ Trial to Explore the Safety, Pharmacology, and Clinical Activity of TGD001 in Immune-Mediated Thrombotic Thrombocytopenic Purpura (iTTP) and Other Thrombotic Microangiopathies

    Lacuna Pharma Pty Ltd

    Immune-Mediated Thrombotic Thrombocytopenic Purpura, Thrombotic microangiopathy

    phase 2 other active

    1 trial

  2. An Open-label, Multicenter, Phase 2 Dose Optimization and Expansion Study to Evaluate the Safety and Efficacy of BB-1701, an anti-human epidermal growth factor receptor 2 (anti-HER2) antibody-drug conjugate (ADC), in Previously Treated Subjects with HER2-positive or HER2-low Unresectable or Metastatic Breast Cancer

    Eisai Co.,

    HER2 positive or HER2-low metastatic breast cancer

    phase 2 other active

    1 trial

  3. An Open-label, Phase I/II First-in-Human, Dose Escalation and Cohort Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic and Anti-tumor Activity of ERK1/2 Inhibitor IPN01194 as Single Agent in Adult Participants with Advanced Solid Tumors

    Ipsen

    Pancreatic Ductal Adenocarcinoma, Melanoma, Head and Neck Squamous Cell Carcinoma, Colorectal Cancer, Solid tumors

    phase 2 other active

    1 trial

  4. An Open-label, Single-arm, Multicenter Pilot Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy and Safety of Pegcetacoplan in Patients with Transplant-associated Thrombotic Microangiopathy (TA-TMA) After Hematopoietic Stem Cell Transplantation (HSCT)

    Swedish Orphan Biovitrum AB (publ)

    Transplant-associated Thrombotic Microangiopathy (TA TMA)

    phase 2 other active

    1 trial

  5. An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301

    Sanofi-aventis Healthcare Pty Ltd

    Asthma

    phase 2 other active

    1 trial

  6. An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent Ξ±- or Ξ²-thalassemia or low-risk myelodysplastic syndromes

    Lacuna Pharma Pty Ltd

    transfusion-dependent Ξ±- or Ξ²-thalassemia or low-risk myelodysplastic syndromes

    phase 2 other active

    1 trial

  7. An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease

    Pharming Technologies B.V.

    Adult patients with primary mitochondrial disease

    phase 2 other active

    1 trial

  8. Analogs, Prostaglandin E1

    Vera Therapeutics

    Covid19

    phase 2 small molecule terminated

    1 trial

  9. Angiotensin (1-7)

    United Therapeutics Europe Ltd

    Traumatic Brain Injury

    phase 2 small molecule active

    1 trial

  10. Anti-CD19 CAR-T

    The First People's Hospital of Lianyungang

    Acute Lymphoblastic Leukemia ,Lymphomas

    phase 2 mab active

    1 trial

  11. Anti-CD19 CAR-T cells and Anti-CD20 CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Lymphoma, Large B-Cell, Diffuse

    phase 2 mab active

    1 trial

  12. Anti-CD40 Agonist Monoclonal Antibody CDX-1140

    United Therapeutics Europe Ltd

    Ovarian Clear Cell Adenocarcinoma

    phase 2 mab active

    1 trial

  13. Anti-GD2-800CW

    AXIM BIOTECHNOLOGIES, INC.

    Neuroblastoma

    phase 2 small molecule active

    1 trial

  14. Anti-PD-1 antibody

    The First People's Hospital of Lianyungang

    Chronic Hepatitis b

    phase 2 small molecule active

    1 trial

  15. Anti-PD-1 antibody

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Gastric or Gastroesophageal Junction Adenocarcinoma

    phase 2 small molecule active

    1 trial

  16. Anti-PD-1 antibody drug named Sintilimab

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Stage IV HCC

    phase 2 small molecule active

    1 trial

  17. Anti-human CCL24 monoclonal antibody (CM-101)

    Chemomab Therapeutics

    Primary Sclerosing Cholangitis

    phase 2 mab active

    1 trial

  18. Antibody UB-421

    United Therapeutics Europe Ltd

    HIV-1 Infection in Adults

    phase 2 small molecule completed

    1 trial

  19. Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet

    Lacuna Pharma Pty Ltd

    Polymyalgia rheumatica

    phase 2 small molecule active

    1 trial

  20. Apart from the AP1189 granulate, the placebo tablet and AP1189 tablet are identical., AP1189 Tablet

    Lacuna Pharma Pty Ltd

    Idiopathic membranous nephropathy and severe proteinuria

    phase 2 small molecule active

    1 trial

  21. Apatinib Combined With SHR-1210 Injection

    The First People's Hospital of Lianyungang

    Hepatocellular Carcinoma

    phase 2 small molecule active

    1 trial

  22. Apatinib Mesylate +SHR-1210

    Chinese University of Hong Kong

    Hepatocellular Carcinoma

    phase 2 other active

    1 trial

  23. Apatinib+ SHR-1210（CamrelizumabοΌ‰

    The First People's Hospital of Lianyungang

    Esophageal Cancer

    phase 2 small molecule active

    1 trial

  24. Apexelsin 5 mg/ml powder for dispersion for infusion., FOLINATE DE CALCIUM HIKMA 10 mg/mL, solution injectable/pour perfusion, OXALIPLATINE KABI 5 mg/ml, solution Γ  diluer pour perfusion., GEMCITABINE HIKMA 38 mg/ml, solution Γ  diluer pour perfusion, FLUOROURACILE TEVA 5000 mg/100 ml, solution Γ  diluer pour perfusion, IRINOTECAN MEDAC 20 mg/ml, solution Γ  diluer pour perfusion

    CERO THERAPEUTICS HOLDINGS, INC.

    Resectable borderline pancreatic adenocarcinoma

    phase 2 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync β€” verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources